

# THE Rheumatologist

An official publication of the ACR and the ARHP serving rheumatologists and rheumatology health professionals

[Conditions](#) [Drug Updates](#) [Professional Topics](#) [Practice Management](#)

[Technology](#) [Resources](#) [About Us](#) [Advertise](#)

You are here: [Home](#) / [Articles](#) / POP1-Based Treatments May Reduce Inflammation

## POP1-Based Treatments May Reduce Inflammation

September 21, 2015 • By [Lara C. Pullen, PhD](#)

Tweet

0

Share

0

G+ Share

0

Share

Email

Print-Friendly Version / Save PDF



**Inflammasomes** are believed to play a critical role in systemic inflammation. Although multiple cell types assemble inflammasomes, researchers still do not know which cells contain the inflammasomes responsible for systemic inflammation. However, studies have demonstrated that inflammasomes containing the adaptor protein ASC are responsible for

cytokine release. Thus, this particular type of inflammasome plays a critical role in the inflammatory response required to clear infection and initiate wound healing after tissue damage. Researchers also believe that uncontrolled and excessive production of inflammasome mediators may result in autoinflammatory and autoimmune diseases. Taken together, this would suggest that to maintain health, the inflammasome response must be tightly controlled.

You Might Also Like

[Lucia de Almeida, a postdoctoral fellow at Northwestern](#)

## Aggregated Neutrophils Limit Inflammation

2014 ACR/ARHP Annual Meeting: Fat's Role in Inflammation

Could Lipids Be a Key to Control Inflammation?

### Also by this Author

Apolipoprotein E Polymorphism Associated with Hyperuricemia in Chinese Population

University in Chicago, and colleagues published the [results](#) of their detailed analysis of inflammasome response online on Aug. 18 in *Immunity* and shed light on inflammasome assembly and regulation.

In a [press release](#), senior author Christian Stehlik, PhD, professor of rheumatology at Northwestern, explains, "Inflammation is controlled by a complex network of regulators that is still poorly understood. Here, we describe a novel inhibitor of the inflammatory response."<sup>2</sup>

Such an advance in understanding should lead to the development of novel therapies for inflammatory diseases. Previously, Dr. Stehlik's laboratory has shown that the PYRIN domain-only protein POP3 inhibits the immune response to virus infection. Several PYRIN domain proteins have also been implicated in [NF- \$\kappa\$ B regulation](#).

In the current study, the investigators turned their attention to the POP1 PYRIN domain protein. Previous studies have found POP1 is regulated by toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling. Dr. de Almeida and colleagues found that POP1 inhibits ASC containing inflammasome assembly by preventing inflammasome nucleation. In doing so, POP1 inhibits caspase-1 activation, the release of IL-1 $\beta$  and IL-18, as well as the release of ASC particles from macrophages. POP1 also inhibits pyroptosis and prevents the propagation of the ASC danger particle-mediated response to bystander cells. Thus, the investigators proposed that POP1 acts in a regulatory feedback loop to decrease excessive inflammatory responses and prevent systemic inflammation. They theorized that it does this by inhibiting the inflammasome-mediated responses to pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). They then tested this hypothesis in mice.

Unfortunately, mice do not have an ortholog for POP1. To get around this obstacle, the investigators engineered mice with transgenic expression of human POP1 in their monocytes, macrophages and dendritic cells. They found these mice were protected

from systemic inflammation triggered by PAMPs, **inflammasome component NLRP3 mutation** and ASC danger particles. The mice also recovered quickly from peritonitis, sepsis and cryopyrinopathy.

The researchers next looked to see if there was an association between POP1 and inflammation in patients. They found patients with sepsis and cryopyrinopathy had less POP1 in their cells than did controls. The results suggest that POP1 may prevent overactivation of the inflammatory response and, thus, prevent diseases caused by excessive inflammation.

To evaluate this possibility, the investigators developed a proof-of-principle drug based on POP1 and found it significantly reduced inflammation in a mouse model of peritonitis. The study results suggest that treatments based on POP1 have the potential to improve many inflammatory diseases.

*Lara C. Pullen, PhD, is a medical writer based in the Chicago area.*

## Reference

1. de Almeida L, Khare S, Misharin AV, et al. **The PYRIN domain-only protein POP1 inhibits inflammasome assembly and ameliorates inflammatory disease.** *Immunity*. 2015 Aug 18;43(2):264–276. doi: 10.1016/j.immuni.2015.07.018. Epub 2015 Aug 11.
2. Dunne N. **News release: Protein found to control inflammatory response.** Northwestern University Feinberg School of Medicine. 2015 Aug 19.

Filed Under: [Conditions](#), [Systemic Inflammatory Syndromes](#)

Tagged With: [Inflammasome](#), [inflammation](#), [POP1 PYRIN domain protein](#)

## You Might Also Like:

